Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 19/20 | 0.85 |
| ▸ | PIK3C2A | O00443 | 2/20 | 0.85 |
| ▸ | PIK3C2B | O00750 | 2/20 | 0.85 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.85 |
| ▸ | PRKDC | P78527 | 2/20 | 0.85 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.85 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.85 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.85 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5343021 | 0.92 | PIK3CG (1.00) | PIK3CGPIK3C2APIK3C2BPIK3CAPRKDC | |
| SCHEMBL5335850 | 0.92 | PIK3CG (0.71) | PIK3CGPIK3C2APIK3C2BPIK3CAPRKDC | |
| SCHEMBL5341150 | 0.86 | PIK3CG (0.64) | PIK3CGPIK3C2APIK3C2BPIK3CAPRKDC | |
| SCHEMBL5339477 | 0.85 | PIK3CG (0.83) | PIK3CGPIK3C2APIK3C2BPIK3CAPRKDC | |
| SCHEMBL2877647 | 0.85 | PIK3CG (0.83) | PIK3CGPIK3C2APIK3C2BPIK3CAPRKDC | |
| SCHEMBL5343531 | 0.84 | PIK3CG (0.67) | PIK3CGPIK3C2APIK3C2BPIK3CAPRKDC | |
| SCHEMBL5343532 | 0.84 | PIK3CG (0.67) | PIK3CGPIK3C2APIK3C2BPIK3CAPRKDC | |
| SCHEMBL5343844 | 0.84 | PIK3CG (0.68) | PIK3CGPIK3C2APIK3C2BPIK3CAPRKDC | |
| SCHEMBL5343840 | 0.84 | PIK3CG (0.68) | PIK3CGPIK3C2APIK3C2BPIK3CAPRKDC | |
| SCHEMBL5346593 | 0.83 | PIK3CG (0.85) | PIK3CGPIK3C2APIK3C2BPIK3CAPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7205295-B2 | Benzoxazin-3-ones and derivatives thereof as therapeutic agents | WARNER-LAMBERT COMPANY LLC (US) | 2007-04-17 | — | — | US | claimed |
| EP-1569653-A1 | BENZOXAZIN-3-ONES AND DERIVATIVES THEREOF AS INHIBITORS OF PI3K | Warner-Lambert Company LLC (US) | 2005-09-07 | — | — | EP | claimed |
| WO-2004052373-A1 | BENZOXAZIN-3-ONES AND DERIVATIVES THEREOF AS INHIBITORS OF PI3K | WARNER-LAMBERT COMPANY LLC (US) | 2004-06-24 | — | — | WO | claimed |
| US-20040121996-A1 | Benzoxazin-3-ones and derivatives thereof as therapeutic agents | BARVIAN NICOLE (US) | 2004-06-24 | — | — | US | claimed |
| US-7205295-B2 | Benzoxazin-3-ones and derivatives thereof as therapeutic agents | WARNER-LAMBERT COMPANY LLC (US) | 2007-04-17 | — | — | US | disclosed |
| EP-1569653-A1 | BENZOXAZIN-3-ONES AND DERIVATIVES THEREOF AS INHIBITORS OF PI3K | Warner-Lambert Company LLC (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004052373-A1 | BENZOXAZIN-3-ONES AND DERIVATIVES THEREOF AS INHIBITORS OF PI3K | WARNER-LAMBERT COMPANY LLC (US) | 2004-06-24 | — | — | WO | disclosed |
| US-20040121996-A1 | Benzoxazin-3-ones and derivatives thereof as therapeutic agents | BARVIAN NICOLE (US) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040121996-A1 | Benzoxazin-3-ones and derivatives thereof as therapeutic agents | XDH, HAX1, CYP4X1 | PIK3CG 4186/4885PIK3C2A 4721/4885PIK3C2B 4743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.